Kinloch Capital’s Pfizer PFE Stock Holding History

Kinloch Capital’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-668	Closed	-$25K	–	161
2020 Q4	$25K	Buy	+668	New	+$24.5K	0.02%	140

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Kinloch Capital's PFE Position: Q1 2021 in Review

Kinloch Capital sold out of Pfizer (PFE) in Q1 2021, closing a stake of 668 shares — an estimated $25K sold.

Kinloch Capital first reported a position in PFE in Q4 2020 and held it in 1 quarter. The position peaked at $25K in Q4 2020. 2,676 funds tracked by Wall St. Rank hold PFE as of Q1 2021.

Kinloch Capital reported no remaining Pfizer position as of Q1 2021 after selling out during the quarter.
Kinloch Capital sold 668 Pfizer shares in Q1 2021, an estimated $25K.
Kinloch Capital first reported a position in Pfizer in Q4 2020 and held it in 1 quarter.
Kinloch Capital's Pfizer position peaked at $25K in Q4 2020.
2,676 funds tracked by Wall St. Rank held Pfizer as of Q1 2021.

Based on Kinloch Capital's 13F filing for Q1 2021, filed 11 May 2021.